EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Insights into Diabetic Kidney Disease

Ewelina Młynarska iD, Dominika Buławska, Witold Czarnik iD, Joanna Hajdys iD, Gabriela Majchrowicz iD, Filip Prusinowski, Magdalena Stabrawa iD, Jacek Rysz, Beata Franczyk

International Journal of Molecular Sciences · 23.09.2024 · 25 (18) · 10222

DOI: 10.3390/ijms251810222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.09.2024. Verfasst von Ewelina Młynarska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland. Hauptthemen laut MEDLINE: Diabetic Nephropathies. Die Arbeit wurde bisher 138-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM), affecting over one-third of type 1 and nearly half of type 2 diabetes patients. As the leading cause of end-stage renal disease (ESRD) globally, DKD develops through a complex interplay of chronic hyperglycemia, oxidative stress, and inflammation. Early detection is crucial, with diagnosis based on persistent albuminuria and reduced estimated glomerular filtration rate (eGFR). Treatment strategies emphasize comprehensive management, including glycemic control, blood pressure regulation, and the use of nephroprotective agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Ongoing research explores novel therapies targeting molecular pathways and non-coding RNAs. Preventive measures focus on rigorous control of hyperglycemia and hypertension, aiming to mitigate disease progression. Despite therapeutic advances, DKD remains a leading cause of ESRD, highlighting the need for continued research to identify new biomarkers and innovative treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesHumansDiabetes Mellitus, Type 2AnimalsKidney Failure, ChronicBiomarkers

Stichwörter der Autor:innen

chronic kidney diseasediabetic kidney diseaseend-stage renal diseasemolecular mechanismspathogenesistreatment

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.
  • Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland.

ORCID-Profile: Ewelina Młynarska, Witold Czarnik, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa

Zitieren

APA

Młynarska, E., Buławska, D., Czarnik, W., Hajdys, J., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2024). Novel Insights into Diabetic Kidney Disease. International Journal of Molecular Sciences, 25(18), 10222. https://doi.org/10.3390/ijms251810222

Vancouver

Młynarska E, Buławska D, Czarnik W, Hajdys J, Majchrowicz G, Prusinowski F, et al. Novel Insights into Diabetic Kidney Disease. International Journal of Molecular Sciences. 2024;25(18):10222. doi:10.3390/ijms251810222

BibTeX
@article{Mynarska2024,
  author = {Młynarska, Ewelina and Buławska, Dominika and Czarnik, Witold and Hajdys, Joanna and Majchrowicz, Gabriela and Prusinowski, Filip and Stabrawa, Magdalena and Rysz, Jacek and Franczyk, Beata},
  title = {Novel Insights into Diabetic Kidney Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {18},
  pages = {10222},
  doi = {10.3390/ijms251810222}
}
Kostenlos starten →